Eli Lilly : LLY

All Eli Lilly Articles

688 Articles

Thomas Richmond | Aug 3, 2026 at 1:17 PM EDT

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works…

Vandita Jadeja | Jul 31, 2026 at 1:30 PM EDT

Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings

Novo Nordisk and Eli Lilly compete in the same blockbuster drug class, yet their 2026 earnings tell dramatically different stories…

Vandita Jadeja | Jul 24, 2026 at 1:30 PM EDT

This Catalyst Makes Eli Lilly a Top Growth Stock in 2026

Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the…

Omor Ibne Ehsan | Jul 22, 2026 at 12:25 PM EDT

The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side

Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly…

Danielle Liverance | Jul 22, 2026 at 6:22 AM EDT

“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits

Jim Cramer is sounding the alarm for investors still riding the AI wave, and his warning carries a specific body…

Vandita Jadeja | Jul 19, 2026 at 9:30 AM EDT

3 Biggest Pharma Giants: Buy, Sell or Hold?

All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very…

Ian Cooper | Jul 16, 2026 at 1:53 PM EDT

Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until…

Vandita Jadeja | Jul 13, 2026 at 2:00 PM EDT

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here…

David Moadel | Jul 10, 2026 at 12:04 PM EDT

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors…

Chris MacDonald | Jul 9, 2026 at 2:28 PM EDT

Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma

Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY | LLY Price Prediction) has added over the…

David Beren | Jul 9, 2026 at 12:18 PM EDT

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good…

Ian Cooper | Jul 9, 2026 at 11:35 AM EDT

Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says…

Joel South | Jul 9, 2026 at 8:00 AM EDT

3 High Growth GLP-1 Biotech Winners to Buy in July

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding…

Rich Duprey | Jul 8, 2026 at 12:02 PM EDT

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow…

Chris MacDonald | Jul 8, 2026 at 8:42 AM EDT

This $1,200 Stock Could Be the Next Massive Stock Split Opportunity

The Number $8.662 billion. That is what Mounjaro alone generated for Eli Lilly (NYSE:LLY | LLY Price Prediction) in the…

1 2 3 4 … 46

Eli Lilly : LLY

All Eli Lilly Articles

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings

This Catalyst Makes Eli Lilly a Top Growth Stock in 2026

The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side

“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits

3 Biggest Pharma Giants: Buy, Sell or Hold?

Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

3 High Growth GLP-1 Biotech Winners to Buy in July

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

This $1,200 Stock Could Be the Next Massive Stock Split Opportunity

Prediction: Amazon Stock Could Be the Sleeper Winner of the AI Boom

Nebius Rises 4% Despite Adding $5.75B in Convertible Debt, Snapping a Six-Session Slide

RUM Group Surges 11% as CEO Vows to Take On CoreWeave and Nebius, Trump Media Holds Flat

The Family Bank: Parents Are Lending Their Kids Mortgage Money at Rates the IRS Itself Publishes, and No One Owes Gift Tax on the Discount.

Everyone's Chasing the Carolinas. Smart Retirees Are Quietly Buying Here Instead

Prediction: Amazon Stock Could Be the Sleeper Winner of the AI Boom

Nebius Rises 4% Despite Adding $5.75B in Convertible Debt, Snapping a Six-Session Slide

Eli Lilly : LLY

All Eli Lilly Articles

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings

This Catalyst Makes Eli Lilly a Top Growth Stock in 2026

The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side

“If You Own Too Much Tech, You’re Going To Be Slaughtered.” Cramer Urges Investors To Take Profits

3 Biggest Pharma Giants: Buy, Sell or Hold?

Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

3 High Growth GLP-1 Biotech Winners to Buy in July

Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

This $1,200 Stock Could Be the Next Massive Stock Split Opportunity

Prediction: Amazon Stock Could Be the Sleeper Winner of the AI Boom

Nebius Rises 4% Despite Adding $5.75B in Convertible Debt, Snapping a Six-Session Slide

RUM Group Surges 11% as CEO Vows to Take On CoreWeave and Nebius, Trump Media Holds Flat

Featured Reads

The Family Bank: Parents Are Lending Their Kids Mortgage Money at Rates the IRS Itself Publishes, and No One Owes Gift Tax on the Discount.

Everyone's Chasing the Carolinas. Smart Retirees Are Quietly Buying Here Instead